Table 1 Baseline characteristics
Total (n = 150) | Thrombus (n = 30) | No thrombus (n = 120) | p-value | |
|---|---|---|---|---|
Age (years) | 63.84 ± 12.82 | 60.93 ± 14.20 | 64.57 ± 12.41 | 0.17 |
Male gender | 103 (68.7%) | 26 (86.7%) | 77 (64.2%) | 0.02 |
BMI (kg/sqm) | 24.27 ± 4.42 | 25.66 ± 5.50 | 23.92 ± 4.06 | 0.06 |
Atherosclerotic risk factors | ||||
Hypertension | 110 (73.3%) | 26 (86.7%) | 84 (70%) | 0.07 |
Diabetes mellitus | 49 (32.7%) | 12 (40%) | 37 (30.8%) | 0.34 |
Dyslipidemia | 108 (72%) | 26 (86.7%) | 82 (68.3%) | 0.05 |
Smoking | 22 (14.7%) | 4 (13.3%) | 18 (15%) | 1.00 |
History of myocardial infarction | 36 (24%) | 13 (43.3%) | 23 (19.2%) | 0.006 |
Coronary revascularization (PCI) | 9 (6%) | 2 (6.7%) | 7 (5.8%) | 1.00 |
History of heart failure | 88 (58.7%) | 19 (63.3%) | 69 (57.5%) | 0.56 |
History of CVA or TIA | 16 (10.7%) | 4 (13.3%) | 12 (10%) | 0.53 |
Atrial fibrillation or atrial flutter | 26 (17.3%) | 3 (10%) | 23 (19.2%) | 0.24 |
Antithrombotic | ||||
Aspirin | 96 (64%) | 21 (70%) | 75 (62.5%) | 0.44 |
Warfarin | 23 (15.3%) | 2 (6.7%) | 21 (17.5%) | 0.17 |
Heart failure medications | ||||
Beta-blocker | 113 (75.3%) | 22 (73.3%) | 91 (75.8%) | 0.78 |
ACEI | 64 (42.7%) | 14 (46.7%) | 50 (41.7%) | 0.62 |
Angiotensin receptor blocker | 32 (21.3%) | 4 (13.3%) | 28 (23.3%) | 0.23 |
Spironolactone | 23 (15.3%) | 2 (6.7%) | 21 (17.5%) | 0.17 |
Furosemide | 72 (48%) | 13 (43.3%) | 59 (49.2%) | 0.57 |
Nitrate | 40 (26.7%) | 9 (30%) | 31 (25.8%) | 0.64 |
Digoxin | 20 (13.3%) | 3 (10%) | 17 (14.2%) | 0.77 |